IPO Tracker 2026: Eikon Clocks Largest IPO Since 2024, Generate Follows as IPO Tap Opens

After a sparse 2025 IPO market (only eight biopharma listings), 2026 is showing a cautious rebound with multiple sizeable biotech offerings and planned listings: Eikon Therapeutics raised $381M (EIKN) to fund late-stage programs including EIK1001, Aktis Oncology raised $318M (AKTS) on Jan. 9 for Actinium-225 radiopharma assets, Veradermics is targeting $256.3M (MANE) for a late-stage extended‑release minoxidil, AgomAb seeks $212.5M (AGMB) for ontunisertib Phase 2b, SpyGlass plans $150M (SGP) for a bimatoprost intraocular lens, and Generate:Biomedicines (GENB) filed to list but has not sized its raise. Analysts characterize the market as more discerning—favoring later‑stage, proven assets—so these offerings and their indications (oncology, ophthalmology, respiratory, GI) will be key drivers of investor appetite and follow-on financing needs in the sector.

Analysis

Market structure: The 2026 micro-IPO wave is concentrated in later-stage, de‑risked assets (radiopharma, registrational immuno-oncology, sustained-delivery ophthalmics, late-stage reformulations) which will command premium valuations and attract crossover funds. That benefits issuers with clear near-term registrational catalysts (EIKN, AKTS, MANE) and hurts discovery-only small caps and SPAC-era plays that lack cash/runway; expect secondary liquidity to be thin for sub-$150m raises. Equity supply into biotech will modestly pressure small-cap biotech indices (XBI-like) over 90–180 days but support issuance in convertibles/high-yield for cash-hungry companies.

Risk assessment: Tail risks include clinical/regulatory failures (CRL or negative Phase 2/3 readouts), platform reproducibility issues for AI-labelled firms (GENB), and a macro shock that re-prices equity risk premia (rates up 75–150bp). Immediate risk window: IPO aftermarket and lock-up expirations (30–180 days); short-term: trial enrollments/readouts over 6–18 months; long-term: approval/commercial milestones 2–4 years. Hidden dependencies include partner/milestone payments and manufacturing scale for radiopharma that can blow out cash burn and delay launches.

Trade implications: Direct longs: favor companies with >$300m cash runway and registrational programs—EIKN (1–2% portfolio), AKTS (1%); buy 12–24 month LEAPS or common shares and size for binary readouts. Pair trade: long MANE (1%) versus short XBI (0.75%) to capture dispersion between late-stage reformulation and broad small-cap risk. Use options: buy EIKN Jan 2028 LEAPS 25% OTM or a 12-month bull-call spread on MANE to cap cost; avoid long-only exposure to AI-platform stories like GENB until clinical proof.

Contrarian angles: Consensus assumes IPO rebound means broad risk-on; it misses likely aftermarket illiquidity and lockup selling that can create 20–40% drawdowns post-listing. AI-tagged biotechs may be under-scrutinized—if GENB cannot show platform-driven candidate differentiation in 6–12 months, expect valuation compression. Historical parallel: 2014–16 biotech window where late-stage deals outperformed discovery names, then a multi-quarter reset; similar outcome probable if macro tightens or trial readouts disappoint.

Key Decisions for Investors

• Establish a 1.5% long position in EIKN (Eikon Therapeutics) within 10 trading days; hedge with buying Jan 2028 LEAPS calls 25% OTM if available or a 12–18 month out-of-the-money call to capture Phase 2/3 upside. Set a hard stop at −30% and trim to half at +50%; objective: capture registrational readout upside over 12–24 months given $381m IPO runway.
• Initiate a 1% long in MANE (Veradermics) via a 12-month bull-call spread (buy ATM call, sell 30% OTM call) to limit premium; target 40–100% return if late-stage efficacy/labeling data or commercialization positioning in 12–24 months. Exit on negative topline or pre-specified delay >6 months to registrational timeline.
• Pair trade: Long AGMB (AgomAb) 0.75% vs short XBI 0.75% (equal notional) to capture relative value if ALK5 programs progress into Phase 2b while broad small-cap biotech sentiment weakens. Rebalance at lock-up expiries (90–180 days) or if AGMB cash runway falls below 12 months.
• Avoid/short small-cap AI-platform biotech GENB (Generate:Biomedicines) until demonstrable clinical differentiation—consider a speculative 0.5% short or buy put spreads 9–12 months with strike ~20% OTM to profit from potential de-rating if no IND/clinical proof within 12 months.